



Living Cell Technologies Ltd

## COMPANY ANNOUNCEMENT

### Quarterly cash flow report period ended September 30<sup>th</sup> 2008

**October XX, 2008 – Melbourne, Australia, Auckland, New Zealand and Boulder, USA – Living Cell Technologies Limited (ASX:LCT; OTCQX: LVCLY)** today announced the quarterly cash flow report for the quarter ended Sept 30<sup>th</sup> 2008. The appendix 4C is attached.

The cash balance at the end of the quarter was \$8,670,253 compared to \$10,767,335 at the end of the quarter to June 30<sup>th</sup> 2008.

The \$2,097,082 decrease was mainly due to normal operational cash expenditure of \$1,877,175 compared to \$1,536,511 last quarter. Expenditure included \$654,668 on research and development (\$615,290 last quarter). Capital expenditure increased to \$253,822 in the quarter, compared to \$37,202 last quarter.

The 30 September ending quarter saw further data being released to confirm clinical benefit to all patients involved in the clinical trial to date. It also saw progress with regards to expanding the LCT pig herd with building consent for the new facility being granted and the commencement of construction (as announced October 23rd). This new facility will be crucial to the successful launch of the New Zealand trial which will now commence in 2009 following approval from New Zealand's Health Minister on October 21, 2008.

During the last quarter Dr Robert Caspari joined LCT as the CEO expanding the expertise of the management team substantially and allowing Dr Paul Tan to focus more fully on the operations aspects of the Company. Dr Caspari said 'this has been a very positive and eventful quarter for LCT with confirmation of the success of our current clinical trial, preparations to allow expansion of the trials and the approval for a New Zealand based clinical trial. It is a very exciting time for the company which is now well poised for future growth and success'.

Dr Robert Caspari  
Chief Executive Officer  
Mob: +1 303-859-5718  
Tel: +1 303-442-2519  
rcaspari@lctglobal.com

Richard Justice  
CFO  
Tel: +64 9 276 2690  
Mob: +64 21 223 4741  
[rjustice@lctglobal.com](mailto:rjustice@lctglobal.com)

Investor and Media  
Relations  
Rebecca Wilson  
Buchan Consulting  
P: +612 9237 2800  
M: +61 (0)417 382 391  
[rwilson@bcg.com.au](mailto:rwilson@bcg.com.au)

Investor and Media Relations  
(U.S.) Leslie Wolf Creutzfeldt  
The Global Consulting Group  
Tel: +1-646-284-9472  
[lwolf-creutzfeldt@hfgcg.com](mailto:lwolf-creutzfeldt@hfgcg.com)

#### **About Living Cell Technologies:** [www.lctglobal.com](http://www.lctglobal.com)

Living Cell is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The company entered clinical trials for its diabetes product in 2007. For the treatment of Huntington's disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. Living Cell's technology enables healthy living cells to be injected into patients to replace or repair damaged tissue

without requiring the use of immunosuppressive drugs to prevent rejection. Living Cell also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

#### **LCT Disclaimer**

*This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information as of October 31st, 2008, and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.*